Quantel Medical ophthalmic combo laser platform garners FDA approval
The Optimis Fusion ophthalmic laser platform from Quantel Medical (Clermont-Ferrand, France), which combines advanced selective laser trabeculoplasty (SLT) photoregeneration therapy and traditional YAG photodisruption treatments for treating cataracts and glaucoma, has received FDA clearance.
Related: Laser cataract surgery: Clearly advanced
The platform's SLT mode for managing glaucoma and lowering intraocular pressure targets melanin-rich cells that absorb the laser energy to induce a healing response, improving the function of the trabecular meshwork. Laser energy is delivered in short, fixed pulses over a large, homogeneous spot size, resulting in no thermal damage. Due to this gentle delivery and lack of permanent destruction to the trabecular meshwork, SLT leaves structures intact, making it a repeatable procedure.
The YAG mode delivers high-performance photodisruption for capsulotomy and peripheral iridotomy surgical procedures. Its Gaussian laser beam profile allows for precise laser delivery at minimum energy levels, avoiding adverse side effects such as lens pitting. Precise tissue targeting is achieved with the advanced two-point aiming beam, allowing for fast and accurate targeting of the capsule, and an adjustable anterior and posterior offset feature allows for easy focus adjustment in front of, behind, or at the point of disruption.
The laser platform was introduced earlier in 2014 in other markets, according to Quantel Medical CEO Jean-Marc Gendre. "Driving the acceptance of this product introduction is the ability to combine a 532 nm mono spot or multispot retina laser, a unique feature to Quantel's laser line," he adds.
For more information, please visit http://www.quantel-medical.com/product-laser-optimis-fusion.php.
-----
Don't miss Strategies in Biophotonics, a conference and exhibition dedicated to development and commercialization of bio-optics and biophotonics technologies!
Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn
Subscribe now to BioOptics World magazine; it's free!